With the arrival of the three child policy, the proportion of China’s child population will probably usher in a new round of growth in the future. For the children’s drug market, this will bring a new round of growth space. The industry predicts that the scale of China’s children’s drug market may exceed 200 billion yuan in 2021, and continue to maintain an average annual double-digit growth rate.
In contrast to the increasing demand, the supply of children’s drug market is lagging behind, facing the problems of few manufacturers, few varieties and few suitable dosage forms. According to the data of the State Drug Administration (nmpa), among the more than 6000 pharmaceutical factories in China, there are more than 30 enterprises with children’s drug production departments, and there are only more than 10 enterprises specializing in children’s drugs.
“At present, the problem of drug safety for children is prominent, and the lack of doctors and drugs is very serious.” Liu Jingping, chairman of the pharmaceutical industry, told reporters in an interview. “Compared with adults, children’s physical function and immune system are immature. When we were young, many of our drugs were a fraction of adult drugs or reduced by children, which is very unsafe.” Liu Jingping said. “In this case, the state strongly supports the development of children’s drugs. At present, there are only more than 70 kinds of children’s drugs in the instructions. In children’s drugs, we are also constantly pursuing the research and development of children’s special drugs and the publicity of children’s drug safety. We should also actively participate in children’s drugs.” Liu Jingping said.
With the help of the policy “Dongfeng”, Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) pharmaceutical industry has gradually emerged in the capital market. As a high-tech enterprise with a complete pharmaceutical industry chain, Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) pharmaceutical was successfully selected into the list of the second batch of specialized and special new “little giants” announced by the Ministry of industry and information technology in 2021.
based on pediatrics
Children’s medicine has the characteristics of few varieties, dosage forms, specifications and labels. The research and development of children’s medicine can be said to be a worldwide problem. The reason is that from an ethical point of view, it is difficult for pediatric drug research and development to conduct clinical trials. In addition, from the perspective of pharmacoeconomics, input and output do not match.
Compared with adult drugs, children’s drugs have longer development cycle, greater investment and low profit. Therefore, there are not many enterprises making pediatrics in China. “We focus on Pediatrics, as well as adult and gynecological drugs. We are an enterprise with a wide range of product types, but the company’s strategic focus is pediatrics.” Liu Jingping told reporters that the company will be committed to building a comprehensive industrial chain of children’s health in China.
As the helmsman of a listed company, Liu Jingping is also a mother. The lack of children’s medicine has always been her focus.
The data show that at present, the number of sick children in China accounts for 19.3% of the total number of sick people. Among the existing 3500 kinds of drugs, only 60 kinds are specially used for children, accounting for about 1.7% of the whole variety of drug preparations.
In 2008, when preparing to establish a pharmaceutical enterprise, Liu Jingping identified pediatric medicine as the development direction. Liu Jingping said, “enterprises should grasp the market demand. If they talk about the market demand without individual demand, they don’t really understand the market. So many enterprises have done adult medicine, and the value of making adult medicine is certainly not as high as that of making children’s medicine.”
Liu Jingping said that children’s medicine is not a reduced version of adult medicine. Most adults can’t take drugs for children. The adverse reactions of children are twice that of adults. Children should first reduce the use of antibiotics. Traditional Chinese medicine has less side effects. We can continuously develop anti infection traditional Chinese medicine and use traditional Chinese medicine to treat upper respiratory system infection and digestive system infection diseases, so as to reduce the damage to children’s body. In addition to oral drugs, external drugs can also choose traditional Chinese medicine to reduce damage to children’s body.
At the beginning of its establishment, Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) pharmaceutical established the corporate mission of “healthy Chinese baby” and made every effort to build a national brand of Chinese children’s medicine. The company is committed to achieving differentiated development, starting from the main categories of Chinese patent medicines for children, and then to the research and development of innovative drugs. At present, the products have covered many drug fields from treatment to prevention, forming the brand characteristics of the company.
After years of development, Xiaoer Feire Kechuan granule, as the company’s gold single product, ranks second in the sales of children’s cold and cough drugs in the OTC market. In addition to the products in the field of respiratory system, the company’s yanyanning granules (capsules) have also become the main products in the field of digestive system. As children’s diseases are mainly concentrated in the respiratory system and digestive system, the company hopes to continuously enrich products in the above two subdivided fields and realize the all-round development of children’s drugs.
rapid growth
Under the leadership of Liu Jingping, Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) pharmaceutical group grew rapidly. ” Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) group has more and more members.” Liu Jingping said that in the process of development, the group has successively acquired or acquired Chengde xinaimin Pharmaceutical Co., Ltd. and Nanning Weiwei Pharmaceutical Co., Ltd., the largest pharmaceutical enterprise in Nanning, Guangxi.
Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) the group quickly completed resource integration through mergers and acquisitions and self construction, and developed into a large pharmaceutical enterprise integrating production, R & D and sales.
Every time “new members” join, what Liu Jingping thinks most is not operation, but “integration”. “It’s easy to achieve normal operation, but it’s difficult to integrate the corporate culture, because the new companies also have their own culture.” Liu Jingping said that the group is to gather into a group, and the integration of subsidiaries into a group is the most difficult and important.
To integrate the company culture, the first thing is to make employees have a sense of belonging. Every time a “new member” joins the group, Liu Jingping only sends two people, the general manager and the chief financial officer, and other management and employees use the same team. “The stability of employees is the first and important step.” Liu Jingping said that the integration will be realized step by step and imperceptibly through training, learning and assessment system.
Since its listing last year, Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) pharmaceutical has continuously optimized its governance structure, increased R & D investment, and successively launched the construction of Haikou Meian children’s medicine intelligent manufacturing base and Guangxi phase II project, which will play a very important role in the future development of the enterprise.
refined medicine
Liu Jingping told reporters that the company is building enterprise product planning in stages. At present, national new drugs are also under research and development.
She believes that the most important thing for the future development of enterprises is R & D. To this end, she set the “four most” goals for the company: to build a benchmark enterprise in the field of children’s pharmacy with the most complete dosage forms, the largest production capacity, the highest scientific and technological content and the strongest quality assurance ability in China.
R & D is the most time-consuming and labor-consuming process. The formula of Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) Xiaoer Feire Kechuan granule of pharmaceutical industry comes from Maxing Shigan Decoction and Baihu Decoction of medical Saint Zhang Zhongjing. In order to verify the efficacy, safety and rationality of the drug, Liu Jingping’s team repeatedly did theoretical research and basic research, continuously improved the standard, accurately used and used the amount, expanded the samples for clinical research, and obtained Xiaoer Feire Kechuan granule.
After the product went on the market, Liu Jingping thought that the drug could be improved. So they spent another five years to improve the medicinal materials and dosage of the products, so as to improve the curative effect. In 2015, the brand-new Xiaoer Feire Kechuan granule was launched.
Since 2015, Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) has successively established academician expert workstation and postdoctoral scientific research workstation to improve the standard of traditional Chinese medicine. Liu Jingping said that in recent years, the government has issued many policies to support and encourage the research and development of innovative children’s drugs, which also has a certain foundation for the enterprise itself. At the same time, in terms of brand construction, it has carried out more popular science education activities, so that Hainan Huluwa Pharmaceutical Group Co.Ltd(605199) pharmaceutical industry can not only have high-end scientific research, but also strengthen basic services, and form a real industrial chain and value chain of the enterprise as a whole.
Riding the east wind of the policy, the field of pediatrics is ushering in a period of rapid development. In view of the lag in the encouragement and guarantee of children’s drug R & D approval policies, in May 2014, six relevant ministries and commissions involved in children’s drug R & D, use and reimbursement jointly participated in promoting the development of children’s drug use, and jointly issued several opinions on ensuring children’s drug use, which is the first comprehensive guidance document on children’s drug use in China. This has made a start at the policy level for China to promote the research and development of children’s drugs and accelerate the speed of approval. It is understood that in terms of the State Food and drug administration, it is stepping up the review of children’s drug registration applications, studying policies such as establishing a drug market monopoly period for children’s drugs, actively cooperating with drug pricing and bidding procurement departments to study and formulate corresponding support and guidance policies to encourage drug enterprises to develop and produce drugs suitable for children.
In the long run, the children’s pharmaceutical industry will enter the shuffle stage, which will bring unprecedented development opportunities for down-to-earth enterprises. Companies with real “core competitiveness” and keeping pace with the times will be in an advantageous position in the future market competition.
(Economic Observer network)
